Meg Krench
Investor at Sanofi Ventures
Cambridge, Massachusetts
Overview
Work Experience
Investor, Sanofi Ventures
2021 - Current
Board Observer
2023
Board Observer
2023
Eligo develops first-in-class proprietary modalities that enable the delivery and expression of therapeutic DNA in target bacterial populations of the microbiome. This technology allows for the first time the in-situ modulation of the microbiome’s composition and function to address human disease with an unprecedented precision.
Board Observer
2023
QurAlis is a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.
Raised $135,500,000.00 from Amgen Ventures, Droia Ventures, MP Healthcare Venture Management, ALS Investment Fund, Polaris Partners, Mission BioCapital, EQT Life Sciences, Mitsui Global Investment, Dolby Family Ventures and Dementia Discovery Fund.
Board Guest
2022
Board Observer
2022
A biotechnology company identifying and targeting novel mechanisms to remove cancer's barriers to normal immunity.
Normunity develops precision immuno-oncology medicines that enable normal immunity against cancer.
Raised $65,000,000.00 from Sanofi Ventures, Taiho Ventures, OUP (Osage University Partners) and Canaan Partners.
Member Board of Directors
2021
Developing first-in-class therapeutics targeting 12-Lipoxygenase for heparin-induced thrombocytopenia and other immune-mediated disorders
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.
Raised $47,460,000.00 from Hatteras Venture Partners, JDRF T1D Fund, Genesys Capital, Pappas Capital, NYBC Ventures and Sanofi Ventures.
Co-Chair, Board Member
2019
Director of BD - External Innovation
2020 - 2021
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Raised $657,308,360.00 from J.P. Morgan Securities Inc., Bank of America Merrill Lynch, Morgan Stanley, Goldman Sachs and Janssen Belgium.
Senior Associate
2018 - 2020
As a Senior Associate, I focused on orphan diseases, including orphan ophthalmology and neuromuscular disorders. RA Capital Management (“RA Capital”) is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes in a continual effort to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides RA Capital’s investment team and portfolio companies with strategic intelligence, market research, and other resources. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, public market dynamics, and many other factors on valuation and business viability.
Associate
2016 - 2018
RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.